Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

OBJECTIVES: * To determine the maximum tolerated dose of sorafenib tosylate when administered with bevacizumab and oxaliplatin. * To determine the effect of this treatment regimen on the complete and partial response rate in patients with metastatic melanoma. * To determine the effect of this treatment regimen on the progression-free and overall survival of patients with metastatic melanoma. OUTLINE: This is a phase I dose-escalation study of sorafenib tosylate followed by a phase II study. * Phase I: Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive oral sorafenib tosylate twice daily on days 1-14. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. * Phase II: Patients receive sorafenib tosylate at the maximum tolerated dose and bevacizumab and oxaliplatin as in phase I. After completion of study therapy, patients are followed for at least 5 years.